Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation

M Herbst, EE Wanker - Current pharmaceutical design, 2006 - ingentaconnect.com
Polyglutamine diseases are autosomal dominant, late-onset neurodegenerative disorders.
Expansion of a polyglutamine (polyQ) tract above a threshold size leads to misfolding and …
被引用次数：47 相关文章

[引用][C] Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and Aggregation

M Herbst, E Wanker - Current Pharmaceutical Design, 2006 - cir.nii.ac.jp
Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and
Aggregation | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation

M Herbst, EE Wanker - Current pharmaceutical design, 2006 - pubmed.ncbi.nlm.nih.gov
Polyglutamine diseases are autosomal dominant, late-onset neurodegenerative disorders.
Expansion of a polyglutamine (polyQ) tract above a threshold size leads to misfolding and …

Therapeutic Approaches to Polyglutamine Diseases: Combating Protein Misfolding and Aggregation

M Herbst, EE Wanker - Current Pharmaceutical Design, 2006 - search.proquest.com
Polyglutamine diseases are autosomal dominant, late-onset neurodegenerative disorders.
Expansion of a polyglutamine (polyQ) tract above a threshold size leads to misfolding and …

Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation.

M Herbst, EE Wanker - Current Pharmaceutical Design, 2006 - europepmc.org
Polyglutamine diseases are autosomal dominant, late-onset neurodegenerative disorders.
Expansion of a polyglutamine (polyQ) tract above a threshold size leads to misfolding and …

Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation

M Herbst, EE Wanker - Current Pharmaceutical Design, 2006 - edoc.mdc-berlin.de
Polyglutamine diseases are autosomal dominant, late-onset neurodegenerative disorders.
Expansion of a polyglutamine (polyQ) tract above a threshold size leads to misfolding and …

[引用][C] Therapeutic approaches to polyglutamine diseases: Combating protein misfolding and aggregation: Therapeutics for protein misfolding diseases

M HERBST, EE WANKER - Current pharmaceutical design, 2006 - pascal-francis.inist.fr
Therapeutic approaches to polyglutamine diseases : Combating protein misfolding and
aggregation : Therapeutics for protein misfolding diseases CNRS Inist Pascal-Francis …

Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation

M Herbst, EE Wanker - Current Pharmaceutical Design, 2006 - edoc.mdc-berlin.de
Polyglutamine diseases are autosomal dominant, late-onset neurodegenerative disorders.
Expansion of a polyglutamine (polyQ) tract above a threshold size leads to misfolding and …

[引用][C] Therapeutic approaches to polyglutamine diseases: Combating protein misfolding and aggregation

M HERBST, EE WANKER - Current pharmaceutical design, 2006 - Bentham